Clinical trial
A Safety and Tolerability Study of ABT-089 in Adults With Attention…
NCT00443391 · AbbVie (prior sponsor, Abbott), Industry · Completed
Key facts
| NCT number | NCT00443391 |
|---|---|
| Title | A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD) |
| Official title | The Long-Term Safety and Tolerability of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD): An Open-Label Extension Study |
| Lead sponsor | AbbVie (prior sponsor, Abbott), Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Attention Deficit Hyperactivity Disorder |
| Intervention type | Drug |
| Interventions | ABT-089 |
| Enrollment | 141 |
| Start date | Feb 1, 2007 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Mar 6, 2007 |
| Last update posted | Jan 18, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: